PolTREG S.A. (PTG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PolTREG S.A. (PTG) has a cash flow conversion efficiency ratio of -0.154x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-7.63 Million ≈ $-2.10 Million USD) by net assets (zł49.48 Million ≈ $13.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of PolTREG S.A. for the company's overall valuation and market capitalisation.
PolTREG S.A. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how PolTREG S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
PolTREG S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PolTREG S.A. ranked by their cash flow conversion efficiency. Explore PTG operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YSX Tech. Co., Ltd Class A Ordinary Shares
NASDAQ:YSXT
|
-0.250x |
|
Ocean Vantage Holdings Bhd
KLSE:0220
|
-0.026x |
|
Progressive Planet Solutions Inc
V:PLAN
|
0.088x |
|
Perimeter Medical Imaging AI Inc
V:PINK
|
-0.343x |
|
Electro-Sensors Inc
NASDAQ:ELSE
|
0.001x |
|
BayWa Aktiengesellschaft
F:BYW
|
-0.099x |
|
Sc Engineering
KO:023960
|
-0.308x |
|
System1 Inc
NYSE:SST
|
-0.611x |
Annual Cash Flow Conversion Efficiency for PolTREG S.A. (2018–2024)
The table below shows the annual cash flow conversion efficiency of PolTREG S.A. from 2018 to 2024. View PolTREG S.A. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł69.23 Million ≈ $19.05 Million |
zł-16.00 Million ≈ $-4.40 Million |
-0.231x | -52.30% |
| 2023-12-31 | zł87.52 Million ≈ $24.09 Million |
zł-13.28 Million ≈ $-3.66 Million |
-0.152x | -78.29% |
| 2022-12-31 | zł101.04 Million ≈ $27.81 Million |
zł-8.60 Million ≈ $-2.37 Million |
-0.085x | -128.55% |
| 2021-12-31 | zł103.01 Million ≈ $28.35 Million |
zł-3.84 Million ≈ $-1.06 Million |
-0.037x | +82.85% |
| 2020-12-31 | zł12.83 Million ≈ $3.53 Million |
zł-2.79 Million ≈ $-767.30K |
-0.217x | -100.11% |
| 2019-12-31 | zł-6.00K ≈ $-1.65K |
zł-1.19 Million ≈ $-327.51K |
198.333x | +14627.96% |
| 2018-12-31 | zł764.00K ≈ $210.26K |
zł-1.04 Million ≈ $-287.05K |
-1.365x | -- |
About PolTREG S.A.
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases. It engages in the development of therapies for the treatment of type 1 diabetes in children, as well as multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland.